CU20120158A7 - POLIPÉPTIDOS DERIVADOS DEL TGFß - Google Patents
POLIPÉPTIDOS DERIVADOS DEL TGFßInfo
- Publication number
- CU20120158A7 CU20120158A7 CUP2012000158A CU20120158A CU20120158A7 CU 20120158 A7 CU20120158 A7 CU 20120158A7 CU P2012000158 A CUP2012000158 A CU P2012000158A CU 20120158 A CU20120158 A CU 20120158A CU 20120158 A7 CU20120158 A7 CU 20120158A7
- Authority
- CU
- Cuba
- Prior art keywords
- polypeptides
- tgfβ
- alk5
- pharmaceutical compositions
- fusion proteins
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se relaciona con las ramas de la Biotecnología y particularmente con polipéptidos mutados de la molécula TGFß cuya secuencia primaria tiene una alta homología con la secuencia del TGFß humano. Estas muteínas pierden la capacidad de interacción con ALK5 pero conservan la interacción con el resto de los receptores que forman parte del complejo receptor (TßEII y TßRII). Tienen la propiedad de antagonizar la señalización de todas las variantes naturales de los ligandos TGFß, dependiente del reclutamiento de ALK5 en el complejo receptor y tienen un efecto inmunomodulador. La presente invención se relaciona con composiciones farmacéuticas que comprenden como principio activo los polipétidos o proteínas de fusión divulgados y con el uso terapéutico de los polipéptidos, proteínas de fusión y composiciones farmacéuticas divulgados dado su efecto modulador del sistema inmune sobre patologías como el cáncer, enfermedades que cursan con fibrosis y en enfermedades infecciosas crónicas.
Priority Applications (29)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU20120158A CU24181B1 (es) | 2012-11-09 | 2012-11-09 | POLIPÉPTIDOS DERIVADOS DEL TGFß |
CA2887455A CA2887455C (en) | 2012-11-09 | 2013-10-30 | Polypeptides derived from tgf.beta. and uses thereof |
PCT/CU2013/000007 WO2014071894A1 (es) | 2012-11-09 | 2013-10-30 | POLIPÉPTIDOS DERIVADOS DEL TGFβ Y SUS USOS |
JP2015540045A JP6298823B2 (ja) | 2012-11-09 | 2013-10-30 | TGFβに由来するポリペプチド及びその使用 |
UAA201505566A UA115678C2 (uk) | 2012-11-09 | 2013-10-30 | МУТАНТНИЙ ПОЛІПЕПТИД TGFβ ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ |
CN201380058181.7A CN104902916B (zh) | 2012-11-09 | 2013-10-30 | 衍生自TGFβ的多肽及其用途 |
EP13805228.7A EP2918284B1 (en) | 2012-11-09 | 2013-10-30 | Polypeptides derived from tgf and uses thereof |
PE2015000549A PE20150890A1 (es) | 2012-11-09 | 2013-10-30 | POLIPEPTIDOS DERIVADOS DEL TGFß Y SUS USOS |
KR1020157011131A KR102093494B1 (ko) | 2012-11-09 | 2013-10-30 | TGFβ-유래 폴리펩티드 및 이들의 용도 |
MX2015005875A MX366060B (es) | 2012-11-09 | 2013-10-30 | Polipéptidos derivados de tgfbeta y sus usos. |
NZ707850A NZ707850A (en) | 2012-11-09 | 2013-10-30 | Polypeptides derived from tgfβ and uses thereof |
ES13805228T ES2857176T3 (es) | 2012-11-09 | 2013-10-30 | Polipéptidos derivados de TGF y usos de los mismos |
EA201590914A EA031990B1 (ru) | 2012-11-09 | 2013-10-30 | МУТАНТНЫЕ ПОЛИПЕПТИДЫ TGFβ И ИХ ПРИМЕНЕНИЕ |
BR112015010145-3A BR112015010145B1 (pt) | 2012-11-09 | 2013-10-30 | Polipeptídeo, e, composição farmacêutica para o tratamento de câncer |
US14/440,627 US9701730B2 (en) | 2012-11-09 | 2013-10-30 | TGFβ-derived polypeptides and uses thereof |
MYPI2015701369A MY173078A (en) | 2012-11-09 | 2013-10-30 | Tgf?-derived polypeptides and uses thereof |
AU2013344022A AU2013344022B2 (en) | 2012-11-09 | 2013-10-30 | Polypeptides derived from TGFBETA and uses thereof |
SG11201502980VA SG11201502980VA (en) | 2012-11-09 | 2013-10-30 | POLYPEPTIDES DERIVED FROM TGFβ AND USES THEREOF |
JOP/2013/0317A JO3502B1 (ar) | 2012-11-09 | 2013-11-03 | البولي بيبتيدات المشتقة من عامل نمو التحويل بيتا واستخداماتها |
TW102140494A TWI615404B (zh) | 2012-11-09 | 2013-11-07 | 轉變生長因子β(TGFβ)衍生之多肽類及彼等之用途 |
ARP130104078A AR093391A1 (es) | 2012-11-09 | 2013-11-07 | POLIPEPTIDOS DERIVADOS DEL TGFb Y SUS USOS |
TNP2015000129A TN2015000129A1 (en) | 2012-11-09 | 2015-04-03 | POLYPEPTIDES DERIVED FROM TGFβ AND USES THEREOF |
PH12015500807A PH12015500807A1 (en) | 2012-11-09 | 2015-04-13 | Tgf�-derived polypeptides and uses thereof |
CO15095702A CO7400865A2 (es) | 2012-11-09 | 2015-04-28 | Polipeptidos derivados del tgfbeta y sus usos |
IL238621A IL238621B (en) | 2012-11-09 | 2015-05-04 | Polypeptides derived from tgfß– and their uses |
CL2015001252A CL2015001252A1 (es) | 2012-11-09 | 2015-05-08 | Polipéptido que antagoniza la actividad de los ligando tgf beta naturales mediada por el receptor alk5; composición farmacéutica que lo comprende; y sus usos. |
ZA2015/04462A ZA201504462B (en) | 2012-11-09 | 2015-06-08 | TGFß-DERIVED POLYPEPTIDES AND USES THEREOF |
HK16101766.2A HK1213781A1 (zh) | 2012-11-09 | 2016-02-18 | 衍生自 β的多肽及其用途 |
JP2018031896A JP6608473B2 (ja) | 2012-11-09 | 2018-02-26 | TGFβに由来するポリペプチド及びその使用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU20120158A CU24181B1 (es) | 2012-11-09 | 2012-11-09 | POLIPÉPTIDOS DERIVADOS DEL TGFß |
Publications (2)
Publication Number | Publication Date |
---|---|
CU20120158A7 true CU20120158A7 (es) | 2014-06-27 |
CU24181B1 CU24181B1 (es) | 2016-04-25 |
Family
ID=49765213
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CU20120158A CU24181B1 (es) | 2012-11-09 | 2012-11-09 | POLIPÉPTIDOS DERIVADOS DEL TGFß |
Country Status (28)
Country | Link |
---|---|
US (1) | US9701730B2 (es) |
EP (1) | EP2918284B1 (es) |
JP (2) | JP6298823B2 (es) |
KR (1) | KR102093494B1 (es) |
CN (1) | CN104902916B (es) |
AR (1) | AR093391A1 (es) |
AU (1) | AU2013344022B2 (es) |
BR (1) | BR112015010145B1 (es) |
CA (1) | CA2887455C (es) |
CL (1) | CL2015001252A1 (es) |
CO (1) | CO7400865A2 (es) |
CU (1) | CU24181B1 (es) |
EA (1) | EA031990B1 (es) |
ES (1) | ES2857176T3 (es) |
HK (1) | HK1213781A1 (es) |
IL (1) | IL238621B (es) |
JO (1) | JO3502B1 (es) |
MX (1) | MX366060B (es) |
MY (1) | MY173078A (es) |
NZ (1) | NZ707850A (es) |
PE (1) | PE20150890A1 (es) |
PH (1) | PH12015500807A1 (es) |
SG (1) | SG11201502980VA (es) |
TN (1) | TN2015000129A1 (es) |
TW (1) | TWI615404B (es) |
UA (1) | UA115678C2 (es) |
WO (1) | WO2014071894A1 (es) |
ZA (1) | ZA201504462B (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11091523B2 (en) * | 2016-11-18 | 2021-08-17 | University of Pittsburgh—of the Commonwealth System of Higher Education | Engineered TGF-β monomers and their use for inhibiting TGF-β signaling |
PL238850B1 (pl) * | 2017-10-19 | 2021-10-11 | Calther Polska Spolka Z Ograniczona Odpowiedzialnoscia | Aktywna forma transformującego czynnika wzrostu beta 1 (TGFβ1) do zastosowania w leczeniu pacjentów z glejakami wielopostaciowymi, w przypadku których to glejaków ponad 5% komórek nowotworowych jest EGFRvIII-pozytywna |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4572899A (en) * | 1998-06-16 | 2000-01-05 | Biogen, Inc. | Variant type ii tgf-beta receptor fusion proteins and methods |
EP1115866A1 (en) * | 1998-09-22 | 2001-07-18 | University of Maryland at Baltimore | Cystine knot growth factor mutants |
US6677432B1 (en) * | 1998-10-07 | 2004-01-13 | Stryker Corporation | Mutations of the C-terminal portion of TGF-β superfamily proteins |
ES2146552B1 (es) * | 1998-11-24 | 2001-04-16 | Inst Cientifico Tecnol Navarra | Peptidos inhibidores de tgf/31 |
US7470769B2 (en) * | 2004-06-30 | 2008-12-30 | Molecular Logix, Inc. | Epidermal growth factor receptor antagonists and methods of use |
US7795389B2 (en) * | 2004-09-28 | 2010-09-14 | The Board Of Regents Of The University Of Texas System | Antagonizing TGF-beta activity with various ectodomains TGF-beta receptors used in combination or as fusion proteins |
CN101365712A (zh) * | 2005-01-11 | 2009-02-11 | 莫勒丘尔洛吉克斯有限公司 | Pan-HER拮抗剂及其使用方法 |
GB0724051D0 (en) * | 2007-12-08 | 2008-01-16 | Medical Res Council | Mutant proteins and methods for producing them |
AU2011243965A1 (en) * | 2010-04-22 | 2012-12-06 | The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center | High affinity leptins and leptin antagonists |
-
2012
- 2012-11-09 CU CU20120158A patent/CU24181B1/es active IP Right Grant
-
2013
- 2013-10-30 MX MX2015005875A patent/MX366060B/es active IP Right Grant
- 2013-10-30 WO PCT/CU2013/000007 patent/WO2014071894A1/es active Application Filing
- 2013-10-30 EA EA201590914A patent/EA031990B1/ru not_active IP Right Cessation
- 2013-10-30 SG SG11201502980VA patent/SG11201502980VA/en unknown
- 2013-10-30 BR BR112015010145-3A patent/BR112015010145B1/pt active IP Right Grant
- 2013-10-30 EP EP13805228.7A patent/EP2918284B1/en active Active
- 2013-10-30 KR KR1020157011131A patent/KR102093494B1/ko active IP Right Grant
- 2013-10-30 NZ NZ707850A patent/NZ707850A/en not_active IP Right Cessation
- 2013-10-30 CA CA2887455A patent/CA2887455C/en active Active
- 2013-10-30 US US14/440,627 patent/US9701730B2/en active Active
- 2013-10-30 JP JP2015540045A patent/JP6298823B2/ja active Active
- 2013-10-30 ES ES13805228T patent/ES2857176T3/es active Active
- 2013-10-30 PE PE2015000549A patent/PE20150890A1/es not_active Application Discontinuation
- 2013-10-30 CN CN201380058181.7A patent/CN104902916B/zh active Active
- 2013-10-30 MY MYPI2015701369A patent/MY173078A/en unknown
- 2013-10-30 AU AU2013344022A patent/AU2013344022B2/en active Active
- 2013-10-30 UA UAA201505566A patent/UA115678C2/uk unknown
- 2013-11-03 JO JOP/2013/0317A patent/JO3502B1/ar active
- 2013-11-07 AR ARP130104078A patent/AR093391A1/es active IP Right Grant
- 2013-11-07 TW TW102140494A patent/TWI615404B/zh active
-
2015
- 2015-04-03 TN TNP2015000129A patent/TN2015000129A1/fr unknown
- 2015-04-13 PH PH12015500807A patent/PH12015500807A1/en unknown
- 2015-04-28 CO CO15095702A patent/CO7400865A2/es unknown
- 2015-05-04 IL IL238621A patent/IL238621B/en not_active IP Right Cessation
- 2015-05-08 CL CL2015001252A patent/CL2015001252A1/es unknown
- 2015-06-08 ZA ZA2015/04462A patent/ZA201504462B/en unknown
-
2016
- 2016-02-18 HK HK16101766.2A patent/HK1213781A1/zh unknown
-
2018
- 2018-02-26 JP JP2018031896A patent/JP6608473B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP12011803A (es) | Polipéptidos inmunomoduladores derivados de la il-2 y su uso terapéutico en cáncer y en infecciones crónicas | |
CY1119058T1 (el) | Ενωσεις ιμιδαζοπυρρολιδινονης | |
CY1122483T1 (el) | Λυοφιλοποιημενες παρασκευες μελφαλανης φλουφεναμιδης | |
EA201590343A1 (ru) | Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний | |
BR112016029848A2 (pt) | proteínas de fusão mic-1 e utilizações das mesmas | |
BR112017025108A2 (pt) | compostos seletivos de pyy e usos dos mesmos | |
EA201992133A1 (ru) | Производные пиперидино-пиримидина для лечения вирусных инфекций | |
EA201691059A1 (ru) | Соединения-пептидомиметики и содержащие их конъюгаты антитело-лекарственное средство | |
MX2016003419A (es) | Metodos y composiciones para sindrome respiratorio coronavirus de oriente medio (mers-cov) inmunogenico. | |
BR112017001940A2 (pt) | proteínas de fusão de interleucina-2/receptor alfa de interleucina-2 e processos de uso | |
EA201691023A1 (ru) | Пептидомиметические соединения и их конъюгаты антитела с лекарственным средством | |
BR112015014462A2 (pt) | vetorização farmacêutica de uma via de sinalização de dinucleotídeos cíclicos de mamíferos | |
BR112016026291A2 (pt) | Derivados do ácido borônico e usos terapêuticos dos mesmos | |
EA201590667A1 (ru) | Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний | |
EA202090547A3 (ru) | Макроциклические деаза-оксипурины для лечения вирусных инфекций | |
CU23923B1 (es) | Polipéptidos derivados de la il-2 con actividad agonista | |
EA202090699A3 (ru) | Композиции, содержащие буфер, вакцины, которые содержат композиции, содержащие буфер, и пути их применения | |
EA201590491A1 (ru) | Иммуногенная композиция | |
TR201910866T4 (tr) | Kanser tedavisi için birleşik preparasyonlar. | |
CY1119957T1 (el) | Θεραπεια νοσηματων με τη χρηση ανοχογονου φαρμακευτικου παρασκευασματος | |
CA2915027A1 (en) | Compositions and methods for administration of vaccines against dengue virus | |
CR20140475A (es) | Agentes terapéuticos para administración subcutánea optimizados | |
EA201501054A1 (ru) | Лечение миопатий и нейродегенеративных заболеваний, связанных с агрегацией белков, путём парентерального введения трегалозы | |
AR095527A1 (es) | Formulaciones de polipéptido fc-factor ix | |
EA201792314A1 (ru) | Фармацевтическая комбинация эверолимуса и дактолисиба |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant of patent |